HIGHLIGHTS
- who: Chunmeng Wang from the Department of Biou2011Therapeutic, the Medical Centre in Chinese PLA General Hospital, Beijing, China have published the paper: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy, in the Journal: (JOURNAL) of September/21,/2019
SUMMARY
CD19-targeted CAR T_cell (CART19) therapy has remarkably improved the outcome of aggressive B cell lymphoma, and 52-83% of patients had a response including 40-58% achieving a complete remission, with a median progression-free survival of 5 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.